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Background
Polyneuropathy, organomegaly, endocrinopathy, M pro-
tein and skin changes (POEMS) syndrome, also known
as osteosclerotic myeloma, Crow–Fukase syndrome or
Takasuki syndrome, is an incompletely understood para-
neoplastic syndrome resulting from an underlying plasm-
aproliferative disorder. Effective treatment of the
underlying plasma cell disorder controls the disease and
results in dramatic reversal of symptoms. Historically,
irradiation of a solitary sclerotic plasmacytoma or low-
dose alkylator along with steroids had been the mainstay
of treatment (1), but in the past decade, the treatment
repertoire has expanded to include high-dose melphalan
with autologous peripheral blood stem cell transplant
(ASCT), as well as novel myeloma therapies (thalido-
mide, lenalidomide) and anti-vascular endothelial growth
factor (VEGF) antibodies (bevacizamib). To date 31
cases of transplant for POEMS have been published (2–
7), 16 of which have been from the Mayo Clinic (8).
Consistently, authors have demonstrated that ASCT is
effective therapy for these patients with improvement of
the neuropathy, skin changes, pulmonary function tests,
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unexpected, excessive morbidity of the procedure in this
cohort of patients. We have therefore updated our expe-
rience with ASCT in patients with POEMS syndrome
with an emphasis on treatment-related morbidity.
Methods
Patients
Between March 1999 and August 2007, 30 patients with
POEMS syndrome have undergone ASCT at Mayo
Clinic, Rochester, 11 of them have been reported in part
previously. Peripheral blood stem cells were collected
using either cyclophosphamide and growth factor
(n = 5) or growth factor alone (n = 25). The median
number of CD34 cells infused was 4.46 · 10
6⁄kg (range
2.39–15.7). Ten patients were conditioned using melpha-
lan 140 mg⁄m
2, 19 received melphalan 200 mg⁄m
2
(Table 1). One patient received carmustine, etoposide,
cytarabine and melphalan. Half of the patients had
scheduled sargramostim beginning on day +6 post-
transplantation.
Standard supportive care with prophylactic antibiotics
was provided to all patients. Data were retrospectively
collected on patients with approval from the Mayo
Clinic Institutional Review Board and in accordance
with Minnesota state law. Charts were reviewed by AD.
Deﬁnitions
A diagnosis of POEMS syndrome is predicated on the
following: (i) polyneuropathy; (ii) monoclonal plasma
cell proliferative disorder; (iii) sclerotic bone lesions, ele-
vations in VEGF, or Castleman disease and (iv) at least
one of the other characteristic features (9).
Bacteremia was deﬁned as a positive blood culture for
any organism, except for coagulase-negative staphylo-
cocci, skin coryneforms and Lactobacillus species, for
which at least two consecutive positive blood cultures
were considered signiﬁcant.
Two published deﬁnitions for engraftment syndrome
(ES) were initially used. The ﬁrst was that of Spitzer
(10), who has developed major and minor criteria for the
syndrome. The major criteria are: temperature >38.3 C
with no identiﬁable infectious etiology; erythroderma
involving more than 25% of body surface area and not
attributable to a medication and non-cardiogenic pulmo-
nary edema and hypoxia. The minor criteria are: hepatic
dysfunction as characterized by a bilirubin >2 mg⁄dL or
a doubling of the transaminases; a doubling of the serum
creatinine; weight gain ‡2.5% over baseline body weight
or transient encephalopathy. To be classiﬁed as ES, all
three major criteria or two major and one minor crite-
rion are required within 96 h of neutrophil engraftment
[absolute neutrophil count (ANC) 0.5 · 10
9⁄L]. The sec-
ond published deﬁnition for ES used was that by Maioli-
no et al. (11), which requires fever within 24 h of ﬁrst
appearance of neutrophil along with any of the follow-
ing: cutaneous rash, pulmonary inﬁltrates or diarrhea. A
third engraftment entity examined was the periengraft-
ment respiratory distress syndrome (PERDS). This is
Table 1 Patient characteristics
n % Median Range
Age 30 48.5 20–70
Gender, M 20 67
Race
Caucasian 25 83
African-American 2 7
Hispanic 2 7
Other 1 3
ECOG PS 2⁄39 ⁄10 30⁄33
Polyneuropathy 30 100
Organomegaly 21 70
Endocrinopathy 24 80
Monoclonal PCD 30 100
Skin involvement 24 80
Extravascular volume
overload
29 97
VEGF elevated, n =1 6 1 5 9 4
Sclerotic bone lesions 27 90
Castleman’s disease 5 17
Immunoglobulin heavy chain isotype
IgA⁄IgG 18⁄76 0 ⁄23
IgM⁄none 1⁄43 ⁄13
DLCO 30 64.5 36–109
RSVP, mmH2O 20 38 21–68
Prior regimens 25 2 0–6
Alkylator based 4 13
Thalidomide or lenalidomide 4 13
Corticosteroids 23 77
Radiation therapy 5 17
Intravenous gamma globulin 13 43
Plasmapheresis 9 30
Time to transplant from
diagnosis, months
30 4 1–57
Time to transplant from
symptoms, months
30 23.5 7–66
Year SCT
2006–2007 11 37
1999–2005 19 63
Mobilization
CTX⁄G5 1 7
G-alone 25 83
Conditioning
Mel200⁄BEAM 20 67
Mel140 10 33
CD34, ·10
6 30 4.46 2.39–15.7
MNC, ·10
8 30 6.86 1.21–21.6
Growth factor post-transplant 15 50
Corticosteroid maintenance 13 43
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injury in the form of hypoxia and⁄or pulmonary inﬁl-
trates on chest radiographs (CXRs) in the absence of
clinical cardiac dysfunction that has to occur within 5 d
of neutrophil engraftment (12).
Corticosteroid use was converted into daily ‘predni-
sone equivalents’. Dexamethasone was considered to be
sevenfold more potent than prednisone and cortisone
one-ﬁfth as potent as prednisone. Intravenous methyl-
prednisolone was considered 1.2-fold more potent than
oral prednisone.
Hematologic responses were deﬁned according to the
International Uniform Response Criteria (13). These cri-
teria include a complete response as the disappearance of
monoclonal protein in the serum and urine by immuno-
ﬁxation as well as fewer than 5% bone marrow plasma-
cytosis. A very good partial response (PR) was also
included as a hematological response category, and
included patients who no longer had a measurable
monoclonal protein in the serum or urine, but were
immunoﬁxation positive (or did not have immunoﬁx-
ation performed to verify complete response). A PR
includes a 50% reduction in the monoclonal protein in
the serum and urine in the absence of any additional evi-
dence of progressive myeloma.
Statistics
Endpoints for the analyses included: ES, need for intuba-
tion, corticosteroid bolus during transplant course and
time to hospital discharge. Time to hospital discharge
relative to peripheral blood stem cell transplantation
(ASCT) was the preferred endpoint over duration of hos-
pitalization because the latter was partially confounded
by early hospitalization for disability related to neuropa-
thy rather than treatment-related toxicity.
Demographic and baseline clinical and laboratory data
between groups were compared using the Kruskal–Wallis
test (14). Except where stated, continuous variables were
treated as continuous variables. Fisher’s exact test was
used to test differences in categorical variables (15). The
pretreatment characteristics used to test outcomes are
those listed in patient characteristics (Table 1). For the
purpose of outcomes’ analyses, transplant-related events
included radiographic changes, fever, weight gain, diar-
rhea, positive blood cultures, admission to the intensive
care unit (ICU) and administration of bolus corticoster-
oids. Survival was calculated from the time of transplant
and survival curves were constructed according to the
Kaplan–Meier method (16). Multivariate analyses were
performed with the use of a stepwise forward regression
model with an entry probability for each variable set at
0.05. All analyses were done using JMP 6.0.0 Statistical
Discovery
TM from SAS (Cary, NC, USA).
Results
Patient characteristics
Of the 30 patients, 67% were male (Table 1). The med-
ian age of the cohort was 48.5 (range 20–70). Time to
transplant from onset of symptoms was 23.5 months and
from diagnosis was 4 months. Most patients had received
prior therapy, most commonly corticosteroids (n = 23),
intravenous gammaglobulin (n = 13), plasmapheresis
(n = 9), but only 40% (n = 12) had received chemother-
apy (cyclophosphamide or IMiDs) or radiation therapy
(n = 3). Eastern cooperative group performance score
was 3 in 33%. Pulmonary function showed decreased dif-
fusion capacity for carbon monoxide (DLCO < 70%) in
57%.
Going into transplant, 13 patients were receiving corti-
costeroids, either a taper from chronic use or adrenal
replacement. Pretransplant characteristics of this group
were the same as compared with their non-chronic ste-
roid using counterparts with the exceptions that they had
more prior therapy (three regimens vs. two regimens,
P = 0.02) and lower DLCOs (57% vs. 73% of expected,
P = 0.02).
Engraftment
Patients had slow neutrophil engraftment, with a median
time to ANC 0.5 · 10
9⁄L of 16 d [interquartile range
(IQR) 15–18], with 10% reaching an ANC of
0.5 · 10
9⁄L by day 13. The time to platelets 20 · 10
9⁄L
and 50 · 10
9⁄L were 14.5 d (IQR 11–22) and 19.5 d
(IQR 15–39), respectively. The median number of plate-
let and erythrocyte transfusions was 5 aphesis units (IQR
2.0–10) and 6 units (IQR 2.5–8.5), respectively.
Treatment-related toxicity
All but four patients were hospitalized during their
transplant course (patient no. 9, 13, 18 and 26). Rates
of fever, diarrhea, weight gain ‡3% of baseline and rash
were high, occurring in 93%, 77%, 53% and 43% of
patients, respectively. Three patients required temporary
dialysis (no. 3, 15 and 20). Twelve patients required sup-
plemental oxygen (no. 3, 4, 5, 7, 15, 16, 17, 20, 21, 22,
23 and 24). Five patients had a bronchoalveolar lavage
performed (no. 3, 4, 15, 16 and 20). One patient had
hemosiderin laden macrophages (patient no. 21). Seven
patients were admitted to the ICU and ﬁve required
endotracheal intubation (patient no. 3, 4, 15, 16 and
20).
Eleven patients had positive blood cultures during
their course (Table 2), including two who had Micrococ-
cus and coagulase-negative Staphylococcus while another
patient had Acinetobacter growing from one catheter
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patient had coagulase-negative Staphylococcus growing
from the long-term central venous catheter on day –4,
which had cleared by day +4 post-transplant. Four of
the instances of bacteremia occurred at days 30, 33 and
81. Overall, there were only ﬁve patients with clinically
signiﬁcant bacteremia from days 2–29 post-ASCT.
The median time to hospital discharge was day 17
(IQR 14.7–25) post-transplant, with the longest hospital-
ization exceeding 170 d. The median number of days
post-ASCT to dismissal from transplant center was 26
(IQR 20–42). Pretransplant characteristics that were
associated with delayed hospital dismissal, deﬁned as
greater than the median of 17 d, included increased age
(P = 0.04) and splenomegaly (P = 0.01), but only
splenomegaly was associated with longer hospitalizations
on multivariate analysis. Transplant events that predicted
for longer hospitalizations included radiographs with
inﬁltrates and⁄or effusions 7–17 d post-transplant
(P < 0.0001), fever (P = 0.03), weight gain >3% of
baseline (P = 0.02), receipt of bolus corticosteroids
(P = 0.0005) and any admission to the ICU
(P < 0.001). On multivariate analysis, only ICU admis-
sion predicted for prolonged hospitalization.
Engraftment syndrome
As shown in Fig. 1A, the classic symptoms of ES – fever,
rash, diarrhea, non-cardiogenic pulmonary edema,
weight gain – were prevalent in these patients, but the
majority did not satisfy the time criteria tied to neutro-
phil recovery as proposed by Spitzer (10) or Maiolino
et al. (11) (Fig. 1B). The time to the ﬁrst complication
consistent with ES was day +9 (IQR 8–11), whereas, the
median time to neutrophil engraftment was day +16
(IQR 14.5–18).
Prospectively, rash was attributed to drugs, with a
resultant change in antibiotic regimen from cefepime to
meropenem. Sixty-three percent of patients had inﬁltrates
and⁄or effusions on CXR at a median of day +12. Of
the 14 patients who initially had a normal CXR with
their ﬁrst fever, six patients went on to have a second
CXR that was abnormal – most commonly with inﬁl-
trates, effusions or both. The ﬁndings may be subtle or
dramatic (Fig. 2).
Depending on the published deﬁnition of ES
employed, 27–47% of patients had the syndrome. If
allowance was made for the delayed neutrophil engraft-
ment, rates exceeded 50% (Fig. 1B). Only ﬁve patients
were prospectively identiﬁed as having ES (patient no.
22, 19, 17, 24 and 25), and they were treated at 10, 11,
12, 13 and 15 d post-transplant with doses of corticoster-
oids from 620 to 1200 prednisone equivalents. Of the ﬁve
patients requiring endotracheal intubation, three satisﬁed
Maiolino’s criteria for ES. Although these three received
bolus corticosteroids during their course, administration
was delayed at 18, 14 and 18 d. The patient whose corti-
costeroids bolus antedated intubation received only pred-
nisone 30 mg⁄d. The same held true for the PERDS.
Although seven patients required oxygen supplementa-
tion at the anticipated time of engraftment, i.e. at a med-
ian of 12 d (IQR 7–17), the time requirement of 5 d
between the need for oxygen and engraftment was satis-
ﬁed in for only two patients.
Risk factors for ES depended on which deﬁnition
of ES was used. No factors other than the deﬁning
Table 2 Positive blood cultures
Patient no. Positive blood cultures (BCx)
Positive BCx
relative to day 0
First
negative
BCx
Growth
after (d)
BCx
(positive⁄
total)
Bottles
(positive⁄
total)
24 Staphylococcus coagulase-negative )4+ 4 1 2 ⁄25 ⁄6
26 Acinetobacter
1 )20
2 11 ⁄21 ⁄3
3 Capnocytophaga +8 +9
2 41 ⁄3–
22 Micrococcus, 1 lumen
1 +8 +10
2 21 ⁄31 ⁄4
Corynebacterium
1 21 ⁄31 ⁄4
29 Staphylococcus coagulase-negative
1 +8 +9
2 21 ⁄31 ⁄4
Micrococcus
1 21 ⁄31 ⁄4
30 Staphylococcus coagulase-negative +10 +16 2 3⁄39 ⁄10
9 Staphylococcus coagulase-negative +11 +14
2 12 ⁄3–
5 Escherichia coli +15 +19
2 13 ⁄3–
17 Staphylococcus coagulase-negative +30 +33
3 12 ⁄22 ⁄5
4 Pseudomonas aeruginosa +33 +35
2 12 ⁄3–
15 Enterococcus faecalis, Bacteroides vulgatus +81 +84
2 11 ⁄31 ⁄3
Also, CMV viremia day +125 1 1⁄31 ⁄3
1Considered a contaminant.
2First redraw.
31⁄3 cultures still positive (line only), so line removed and cultures not rechecked.
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the neutrophil count. In contrast, three features stood
out as risk factors for the modiﬁed Spitzer and modiﬁed
Maiolino deﬁnitions (Fig. 1B): baseline splenomegaly,
baseline lymphadenopathy and mobilization with growth
factor alone (Table 3). In a multiple logistic model, type
of mobilization (P = 0.02) and either lymphadenopathy
(P = 0.03) or splenomegaly (P = 0.004) retained signiﬁ-
cance for the modiﬁed Spitzer, but for modiﬁed Maioli-
no, only type of mobilization (P = 0.02) and
lymphadenopathy (P = 0.002) were signiﬁcant. Surpris-
ingly, scheduled sargramostim after transplant did not
affect risk of ES.
The role of corticosteroids in POEMS patients
undergoing PBSCT
As mentioned, 13 patients began their transplant on
maintenance corticosteroids. Their post-transplant course
differed slightly from those who were not on chronic cor-
ticosteroids: later time to ﬁrst fever and rash (day +10.5
vs. +8.0, P = 0.002; and day +12 vs. +10, P = 0.01,
respectively); and later time to corticosteroid bolus (day
+12 vs. day +11, P = 0.03). The number of patients
who received corticosteroid bolus was comparable in the
maintenance vs. no maintenance group. There was no
difference in the number of transfusions they required,
their time to neutrophil or platelet engraftment or their
risk of bacteremia or of developing ES.
We postulated that patients with ES, who received
corticosteroids in a timely manner, would fare better
than those who did not. Fourteen patients received corti-
costeroid boluses (range 20–1200 mg⁄d prednisone equiv-
alents) during the course of their transplant from day
+9 to day +57, median 12.5 (Fig. 1B). Indications were
ES in ﬁve, diffuse alveolar hemorrhage in one (patient
no. 20), drug rash in two (patient no. 8 and 10), stress
dose for adrenal insufﬁciency in four (patient no. 15, 16,
21 and 23) and acute respiratory distress syndrome in
two (patient no. 3 and 4). Patients receiving corticoster-
oids for the indications of drug rash or adrenal insufﬁ-
ciency received lower doses (20–40 mg⁄d). The
prednisone dose used for the indication of acute respira-
tory distress syndrome was 120 mg⁄d in one patient and
500 mg⁄d in the other.
Ninety-three percent of patients receiving bolus corti-
costeroids had baseline organomegaly as compared with
an incidence of organomegaly of 50% in patients who
did not require bolus corticosteroids, P = 0.01, or stated
slightly differently, 79% of patients with baseline spleno-
megaly received bolus corticosteroids; whereas only 18%
of those without were given bolus corticoste-
roid, P = 0.001. A similar relationship existed for
A
B
Figure 1 Engraftment syndrome (ES): signs
and deﬁnitions. (A) Timing of neutrophil engraft-
ment relative to other ES entities. (B) ES
deﬁnitions and rates. M-, ‘modiﬁed’ Spitzer and
Maiolino engraftment deﬁnitions relax the 96
and 24 h neutrophil requirements; CS, cortico-
steroid; CTX, cyclophosphamide; M, cyclo-
phosphamide mobilization; C,
cyclophosphamide used for 2–3 cycles prior to
coming to transplant; SCT, stem cell transplant
patient number. Patients no. 1–11 are those
previously reported.
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and 33%, P = 0.05. There was also a higher percentage
of patients with a baseline pericardial effusion (89% vs.
44%, P < 0.05) receiving bolus corticosteroids. In con-
trast, there was no difference in their baseline ﬂuid reten-
tion, their DLCO, conditioning regimens, their scheduled
use of post-transplant growth factors.
Patients receiving bolus corticosteroids were more
likely to meet criteria for ES (Maiolino, P = 0.07; Spit-
zer P = 0.06; modiﬁed Maiolino, P = 0.003 and modi-
ﬁed Spitzer, P = 0.0003). They were more likely to have
had weight gain due to ﬂuid retention (0.005), rash
(P = 0.04), delayed neutrophil and platelet engraftment
(P = 0.04 and 0.02, respectively), higher platelet and
erythrocyte transfusion needs (P = 0.0004 and <0.0001,
respectively), have spent time in the ICU (P = 0.0005)
and had longer times to hospital dismissal (P = 0.0005).
All but one patient who received a corticosteroid bolus
had an abnormal CXR, P = 0.002. These patients were
no more likely to have bacteremia than those who did
not get corticosteroids, but they were more likely to
require mechanical ventilation.
In an effort to separate the use of corticosteroid
boluses as a reactive strategy of desperation from a pro-
active therapeutic strategy, we evaluated the impact of
the timing of bolus corticosteroids on outcomes. There
were no signiﬁcant baseline differences between the early
and late groups. However, those seven patients who
received corticosteroids before day 13 had superior out-
comes as compared with the seven who received them
A
B
Figure 2 Engraftment syndrome (ES) radio-
graph ﬁndings. (A) Day +8 PBSCT demonstrat-
ing relatively normal CXR despite fever and
diarrhea. (B) Day +11 PBSCT (same patient)
demonstrating increased heart size, diffuse
interstitial inﬁltrates throughout both lungs with
alveolar inﬁltrates in the lower lungs.
Table 3 Risk of engraftment syndrome
Modiﬁed Spitzer ES Modiﬁed Maiolino ES
ES, n = 15 No ES, n =1 5 P-value ES, n = 17 No ES, n =1 3 P-value
Splenomegaly, n =1 4 1 0⁄15 4⁄15 0.03 11⁄17 3⁄13 0.02
Lymphadenopathy, n =9 8⁄15 1⁄15 0.005 9⁄17 0⁄13 0.002
Any CTX, n =8 2⁄15 6⁄15 NS 2⁄17 6⁄13 0.03
Mobilization CTX⁄G, n =5 0⁄15 5⁄15 0.01 0⁄17 5⁄13 0.005
Any CTX, cyclophosphamide used as therapy or for mobilization.
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ment of maximum temperature, lower likelihood of requir-
ing mechanical ventilation and earlier hospital dismissal.
There was a trend toward a lower transfusion requirement
and a higher maximum temperature, but given the small
sample size, these differences were not signiﬁcant.
Overall survival and response
With a median follow-up of 19 months, there has been
only one death at 4 months, which was previously
reported (8). According to the international response cri-
teria (13), 62% have achieved a complete hematological
response, 17% a very good PR, 3% a PR and 10% had
less than a PR. One patient is too early for assessment;
another died prior to assessment and one had no mea-
surable disease other than lymphadenopathy, which
resolved. All evaluable patients have derived clinical ben-
eﬁt from the therapy, including those patients who
achieved less than a PR. Of these three patients without
signiﬁcant hematological response, two had baseline
VEGF measurements. Their respective plasma VEGF
levels decreased from 331 pg⁄ml to undetectable and
from 713 to 117 pg⁄ml despite the lack of hematological
response. The other patient has normal VEGF levels
more than 3 yr post-transplant. One patient who
achieved only minimal hematological response received
consolidative radiation to persistent ﬂuorodeoxyglucose
positron emission tomagram positive bone lesions, with-
out any further reduction in his M-protein. There has
been one relapse 65 months post-ASCT.
Discussion
We and others have demonstrated the value of high-dose
chemotherapy with peripheral blood stem cell transplant
in patients with POEMS syndrome (2–8, 17–25). This
report takes these initial observations several steps fur-
ther. The median overall survival for this cohort has not
been reached, and the treatment-related mortality was
3%. Patients with POEMS appear to be at high risk for
an engraftment-type syndrome, which is associated with
considerable morbidity. In this work, we describe several
novel ﬁndings including the predictive power of spleno-
megaly for a complicated post-transplant course. In addi-
tion, important clinical improvements and reductions in
plasma VEGF levels can occur in the absence of signiﬁ-
cant drops in the monoclonal protein.
In our previous report of 16 patients with POEMS, we
were impressed by excessive peritransplant complications,
but with excellent long-term clinical outcomes (8). What
stood out previously was a rate of ICU admission of
nearly 40%. We attributed much of this to poor pulmo-
nary reserve – both neuromuscular restriction and diffu-
sion capacity deﬁcits. This, however, did not explain the
entire clinical course, including culture-negative fevers
and excessive weight gain, observed in these patients.
Over time it became increasingly evident that these
patients were exhibiting signs of an engraftment-type
syndrome, which in real-time was under recognized. For
our last 12 transplants (Fig. 1B), there has been a height-
ened awareness of this complication leading to faster
response with corticosteroids. Although it did not reach
Table 4 Patient outcomes based on bolus corticosteroid usage
1
No steroid (n = 16) Steroid £D12 (n = 7) Steroid >D12 (n =7 ) PP , early vs. late CS
ES: M⁄S⁄mM⁄mS, n
2 5⁄2⁄5⁄34 ⁄4⁄6⁄65 ⁄2⁄6⁄6N A N A
Weight change, % 0.6 (0.42–6.7) 6.7 (3.6–27.2) 11.2 (–2.1 to–23.2) 0.005 NS
Rash, % 27 71 43 NS NS
Diarrhea, % 73 86 86 NS NS
Tmax,  C 39 (37.8–41) 40.1 (39–41.1) 38.9 (38.7–40.8) 0.08 0.07
1st fever, day 10 (6–15) 8 (7–9) 12 (8–146) 0.007 0.007
Abnormal CXR1, % 13 71 71 0.03 NS
Ventilator, % 0 14 71 0.004 0.03
First WBC, day 12 (8–21) 14 (12–14) 14 (12–17) 0.03 NS
ANC500, day 15 (12–29) 16 (14–115) 18 (15–45) 0.08 NS
PLT20, day 12 (8–41) 20 (11–115) 24 (9–170) 0.05 NS
PLT50, day 15 (11–192) 32 (16–115) 56 (13–551) 0.03 NS
RBCs, units 3 (2–8) 6 (4–31) 11 (6–64) 0.0008 NS
PLTS, apheresis units 2 (1–9) 9 (4–51) 18 (4–60) 0.0004 NS
Hospital dismissal, day 15 (13–36) 21 (15–69) 41 (16–175) 0.009 0.05
1Except where stated otherwise, values are expressed as median (range).
2ES, engraftment syndrome according to deﬁnition of Maiolino (11) (M), Spitzer (10) (S), modiﬁed Mailino (mM) and modiﬁed Spitzer (mS) – see
text and Fig. 1 for deﬁnitions.
ANC500, absolute neutrophil count >0.5 · 10
9⁄L; PLT20, platelet engraftment to 20 · 10
9⁄L; PLT50, platelet engraftment to 50 · 10
9⁄L; RBCs,
red blood cell transfusion; PLTS, platelet transfusions.
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missed from hospital after day 24 has decreased from
33% to 8%. Moreover, nearly 60% of the more recent
cohort has received bolus corticosteroids as compared
with fewer than 40% of the earlier cohort. Of those
receiving corticosteroids, more patients have been receiv-
ing them earlier and at higher doses.
Given the delayed neutrophil engraftment seen in this
patient population, we took liberties with the deﬁnition
of ES by loosening the time restriction of peripheral
blood neutrophil reconstitution. In the context of
engraftment, the peripheral neutrophil counts are surro-
gates for more complex cellular, cytokine and chemokine
interactions. Since there is no standard deﬁnition of ES,
we used a total of four deﬁnitions of ES and one for
PERDS: (i) Spitzer (10); (ii) Maiolino et al. (11); (iii and
iv) a variant of each, which uncoupled the timing of
peripheral blood neutrophil recovery and symptoms.
Using these various deﬁnitions, as many as 57% of
patients developed ES. The deﬁnition, which seemed to
best reﬂect reality, was the Spitzer modiﬁcation. Using
this deﬁnition, 50% of our patients would be labeled as
having had a type of ES.
The early identiﬁcation of an ES is more than an aca-
demic exercise. Based on both our own experience and
retrospective reviews of the literature (10, 26–28), corti-
costeroids are an important adjunctive therapy in
patients with this condition and they decrease the dura-
tion of the syndrome. In the POEMS cohort, we have
observed an almost instantaneous cessation of unrelent-
ing high fevers, followed by diuresis and improvement of
rash and diarrhea. One of the most common reasons for
delayed institution of corticosteroids has been the con-
cern that these patients are septic. The very high fevers,
the third-spacing and the dropping blood pressures are
all consistent with sepsis. Although corticosteroids are
immunosuppressive, a short course should not affect the
outcome even in a septic patient if they are on broad
spectrum antibiotics (29). A major question in the ﬁeld
of ES is the dose of corticosteroids sufﬁcient to terminate
the process. Based on our experience with POEMS
patients, prednisone doses of <0.5 mg⁄kg are not sufﬁ-
cient. More recently, we have been using methylpredniso-
lone 500–1000 mg⁄d for 2–3 d followed by a rapid taper,
but certainly one could also consider doses of
1–2 mg⁄kg.
Our study provokes as many questions as answers,
which will require further study. Why would patients
with POEMS syndrome have rates of fever, diarrhea,
weight gain of ‡3% baseline and rash of 93%, 77%,
53% and 43%, respectively? One could postulate that
patients with POEMS syndrome have an aberrant cyto-
kine milieu that is ampliﬁed and exaggerated by the pro-
cess of marrow reconstitution. It is known that the vast
majority of patients with POEMS have signiﬁcant eleva-
tions in VEGF (22, 30–32), and many have increased
levels of tumor necrosis factor-alpha (TNF-a) and inter-
leukin-1b (IL-1b) (33). Marrow reconstitution has been
shown to be associated with signiﬁcant increases in the
concentration of circulating macrophage colony-stimulat-
ing factor (M-CSF), erythropoietin, IL-6 and TNF-a,
reaching near maximal values at around day +12 (34).
The cytokine burst appears to predate neutrophil
engraftment.
Why would splenomegaly predict for a more compli-
cated course? The answer is unclear. Patients with
POEMS syndrome are quite heterogeneous, but there is
little understanding about that heterogeneity from a
pathogenic standpoint. Splenomegaly in and of itself has
not been shown to be an adverse prognostic ﬁnding in
the retrospective reviews that have evaluated clinical out-
comes of POEMS patients. One could speculate that the
spleen serves as a reservoir of cells that participate in a
feedback loop of cytokine⁄chemokine stimulation that
occurs during engraftment.
The other peculiar aspect relates to their transfusion
need and their delayed engraftment, even among those
patients with uncomplicated courses. In a myeloma patient
receiving an up-front ASCT, the median number of eryth-
rocyte and platelet transfusions is two of each (35). Con-
trast those ﬁgures to those of the POEMS patients. Up to
70% required transfusion of more than 3 units of erythro-
cytes, and almost 60% required more than 3 units of
apheresis platelets. Only 7% and 33% of patients had en-
grafted their neutrophils and platelets, respectively, by day
12. Once again, the only explanations that can be posited
have to do with cytokine milieu. In their study of cytokine
levels in the weeks following bone marrow and peripheral
blood stem cell transplantation, Rabinowitz et al. found
that M-CSF was the best predictor of platelets required,
followed by IL-6 (34). High M-CSF and IL-6 both corre-
lated with an increased demand to platelet transfusion.
This needs to be studied prospectively in patients with
POEMS syndrome.
The ﬁnal curiosity elicited by this study was the partial
disconnect between clinical response and hematological
response. The majority of patients achieved either a com-
plete response or a very good partial response, but we
observed three patients with less than a PR, all of whom
had improvements in their neuropathy and other clinical
ﬁndings. These patients highlight the relative lack of
importance of the monoclonal protein and point to other
factors in the etiology of this disorder. VEGF is the
extracellular signaling peptide most consistently elevated
in patients with POEMS syndrome and is likely the pre-
ferred serial marker to follow a patient’s status (36).
In conclusion, POEMS syndrome is a complex syn-
drome characterized by elevations in VEGF and other
POEMS periengraftment Dispenzieri et al.
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with peripheral blood stem cell transplantation is an
effective treatment strategy for selected patients. Patients
are at high risk for an engraftment-type syndrome, which
may be corticosteroid responsive. Splenomegaly and
lymphadenopathy appear to raise the risk for post-trans-
plant complications.
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